The AMPA antagonist perampanel is proving to be an effective and well tolerated adjunctive treatment for people with drug-resistant epilepsy, Australian real world results suggest. In a retrospective observational study of 387 patients managed in nine Australian epilepsy centres, late add-on treatment with perampanel resulted in 21.7% responder rates (at least 50% reduction in seizure ...
Perampanel effective in drug-resistant epilepsy: Australian study
By Michael Woodhead
6 May 2021